IP Library › Granted Patent US 11,925,722
Granted Patent B2
US 11,925,722 · App. 16/767,579 · Granted Mar 12, 2024

Composition of a calcium phosphate and an additive compound containing a phosphate or phosphonate group

Inventors: Philip Procter (Divonne les Bains, FR); Michael Pujari-Palmer (Uppsala, SE); Gerard Insley (Limerick, IE); Håkan Engqvist (Uppsala, SE)
Assignee: GPBIO LTD.
A61L24/02A61K6/58A61K6/838A61L27/12A61L27/365A61M5/19A61L2400/06A61L2430/12A61L2430/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,925,722
App. No.
16/767,579
Granted
Mar 12, 2024
Kind
B2
Abstract

The present invention relates to a composition of a calcium phosphate such as tetracalcium phosphate or α-TCP and an additive compound selected from nucleic acid or nucleotides, phospho(enol)pyruvic acid and phosphocreatine. The composition may be used as a tissue adhesive.

Claims (22)

1. An aqueous composition comprising:

a. an aqueous solution;

b. a calcium phosphate compound wherein the calcium phosphate is α-TCP;

c. an additive compound selected from phosphocreatine, wherein the carboxylic acid of the phosphocreatine may be in acid form or the corresponding salt;

wherein the calcium phosphate compound represents 10-90 wt % and the additive compound represents 10-90 wt % of the solid content in the composition,

wherein the composition comprises an acid, said acid optionally being the carboxylic acid of the additive compound, and has an acid concentration of 1.0-4.0M, and

wherein the liquid/powder (L/P) ratio is 0.16-0.45.

2. The aqueous composition according to claim 1 , wherein the composition further comprises an accelerator or retardant which is sodium citrate.

3. The aqueous composition according to claim 1 , wherein the amount of the additive compound is 25-75 wt %.

4. The aqueous composition according to claim 1 , wherein the L/P ratio is 0.20-0.35.

5. A biological tissue adhesive comprising the composition according to claim 1 .

6. A bone filler comprising the composition according to claim 1 .

7. A dental implant comprising the composition according to claim 1 .

8. A method of adhering a first tissue to a second surface using the tissue adhesive according to claim 5 comprising:

a. applying the tissue adhesive according to claim 5 to the first tissue or to the second surface and optionally leave it for a period of time of about 20 seconds to about 60 seconds;

b. bringing the first tissue and the second surface into contact with each other;

c. optionally applying a pressure on the first and second tissue for a period of time of about 1 to about 3 minutes; and

d. letting the tissue adhesive cure.

9. A kit for preparing the composition according to claim 1 comprising at least two containers wherein any one container in the kit can contain any of the aqueous solution, the additive compound, the calcium phosphate compound or a combination thereof, with the proviso that both the additive compound and the calcium phosphate compound cannot be present in the same container as the aqueous solution; and

wherein the amount of aqueous solution, additive compound, calcium phosphate compound in the containers is such that when mixed the composition according to claim 1 is obtained.

10. The aqueous composition according to claim 1 wherein the L/P ratio is 0.20-0.30.

11. The aqueous composition according to claim 2 , wherein the sodium citrate is in the range of 5-66% weight/volume.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2021
From: GPBIO LIMITED
To: BIOMIMETIC INNOVATIONS LIMITED
Reel/Frame 056561/0063 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2020
From: PROCTER, PHILIP; PUJARI-PALMER, MICHAEL; INSLEY, GERARD; ENGQVIST, HAKAN
To: GPBIO LTD.
Reel/Frame 053998/0887 →
Priority Claims (1)
SE 1751483-7 · Dec 1, 2017 · national
Continuity (1)
Related Publication 20200384147A1 · Dec 10, 2020